Compare AGD & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGD | ABEO |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 296.6M | 280.2M |
| IPO Year | 2006 | 2005 |
| Metric | AGD | ABEO |
|---|---|---|
| Price | $10.44 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 109.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.25 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $8.46 | $3.93 |
| 52 Week High | $13.98 | $7.54 |
| Indicator | AGD | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 25.85 | 31.52 |
| Support Level | $10.25 | $4.00 |
| Resistance Level | $11.74 | $5.62 |
| Average True Range (ATR) | 0.30 | 0.19 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 1.12 | 2.29 |
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors, among others.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.